Breathe Well Live Well
|
AstraZeneca licenses experimental asthma drug
Philadelphia Business Journal (blog) AstraZeneca entered into an exclusive global licensing agreement Thursday for an experimental asthma drug being developed by Synairgen, a United Kingdom biopharmaceutical company. Under the terms of the deal, AstraZeneca (NYSE: AZN) will make an … |
View full post on asthma – Google News
|
AstraZeneca licenses rights to Synairgen asthma drug
Yahoo News LONDON (Reuters) – AstraZeneca has struck a deal worth up to $232 million in milestone payments to license in rights to a drug from Synairgen for viral-induced exacerbation in asthma. Britain's second biggest drugmaker – subject of a takeover bid by … |
View full post on asthma – Google News
|
Sanofi licenses hard-to-make asthma drug to Acton
FiercePharma Manufacturing Acton used the same approach in 2009–one year after it was formed–with Forest Labs ($FRX) to win a licensing deal for asthma treatment Aerospan. The NDA for this HFA-propelled aerosol inhaled corticosteroid was approved by the FDA in 2006. … Acton Pharmaceuticals, Inc. Announces License Agreement With |
View full post on asthma – Google News
 Stockopedia |
CORRECT: Vectura Licenses Patents To GlaxoSmithKline
Wall Street Journal VX) generics unit Sandoz handed back the US rights to VR315, a generic version of an asthma drug, to Vectura. Analysts said it signaled Sandoz wasn't sure … INTERVIEW: Vectura Patents For GSK's 573719 And 642444 Vectura and GlaxoSmithKline sign agreement over asthma patents Vectura boosted by deal with GSK worth over $30 million upfront plus royalties … |
View full post on asthma – Google News